ESR1 and breast carcinoma: The KEYNOTE-756 and CheckMate-7FL trials demonstrated that adding PD-L1 inhibitors (pembrolizumab and nivolumab, respectively) to NAC significantly improved pCR rates in patients with early-stage, high-risk, ER + HER2- breast cancer [14, 15].